

BEFORE THE
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE
TO THE
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
ORGANIZED PURSUANT TO THE
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
SPECIAL MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: MONDAY, MARCH 29, 2010
4 P.M.

REPORTER: BETH C. DRAIN, CSR
CSR. NO. 7152

BRS FILE NO. : 87053

BARRISTERS' REPORTING SERVICE

I N D E X

ITEM	DESCRIPTION	PAGE NO.
CALL TO ORDER		3
ROLL CALL		3
	CONSIDERATION OF COMPENSATION TERMS OF VICE PRESIDENT OF RESEARCH AND DEVELOPMENT	PULLED
	CONSIDERATION OF GUIDANCE AND CIRM'S MEDICAL AND ETHICAL STANDARDS REGARDING THE USE OF PREVIOUSLY NIH APPROVED LINES IN CIRM-FUNDED RESEARCH AND ADDITIONAL LINES THAT ARE COMPATIBLE TO CIRM'S RECOMMENDATIONS TO THE NIH AND/OR WOULD BE GRANDFATHERED OR APPROVED UNDER THOSE RECOMMENDATIONS	5
PUBLIC COMMENT		17

BARRISTERS' REPORTING SERVICE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MONDAY, MARCH 29, 2010

4 P.M.

CHAIRMAN KLEIN: ALL RIGHT. MELISSA, IF WE COULD CALL THE MEETING TO ORDER, IF YOU COULD PROCEED WITH A ROLL CALL, PLEASE.

MS. KING: RICARDO AZZIZ. ROBERT PRICE FOR ROBERT BIRGENEAU.

DR. PRICE: HERE.

MS. KING: FLOYD BLOOM. GORDON GILL FOR DAVID BRENNER.

DR. GILL: HERE.

MS. KING: WILLIAM BRODY.

DR. BRODY: HERE.

MS. KING: SUSAN BRYANT. MARCY FEIT. MICHAEL FRIEDMAN. LEEZA GIBBONS.

MS. GIBBONS: HERE.

MS. KING: MICHAEL GOLDBERG. SAM HAWGOOD. BOB KLEIN.

CHAIRMAN KLEIN: HERE.

MS. KING: SHERRY LANSING. GERALD LEVEY. TED LOVE.

DR. LOVE: HERE.

MS. KING: ED PENHOET.

DR. PENHOET: HERE.

BARRISTERS' REPORTING SERVICE

1 MS. KING: PHIL PIZZO.
2 DR. PIZZO: HERE.
3 MS. KING: CLAIRE POMEROY.
4 DR. POMEROY: HERE.
5 MS. KING: FRANCISCO PRIETO.
6 DR. PRIETO: HERE.
7 MS. KING: ELIZABETH FINI FOR CARMEN
8 PULIAFITO.
9 DR. FINI: HERE.
10 MS. KING: ROBERT QUINT. JEANNIE FONTANA
11 FOR JOHN REED. DUANE ROTH. JOAN SAMUELSON. DAVID
12 SERRANO-SEWELL.
13 MR. SERRANO-SEWELL: HERE.
14 MS. KING: JEFF SHEEHY.
15 MR. SHEEHY: HERE.
16 MS. KING: JON SHESTACK. OSWALD STEWARD.
17 DR. STEWARD: HERE.
18 MS. KING: ART TORRES.
19 MR. TORRES: HERE.
20 MS. KING: I'LL CIRCLE BACK.
21 CHAIRMAN KLEIN: DONALD DAFOE WAS GOING TO
22 BE HERE FOR DR. AZZIZ.
23 MS. KING: FLOYD BLOOM. SUSAN BRYANT.
24 MARCY FEIT. MICHAEL GOLDBERG, SAM HAWGOOD.
25 ANYONE HAS JOINED THE CALL THAT DID NOT

BARRISTERS' REPORTING SERVICE

1 HEAR YOUR NAME IN THE ROLL CALL, PLEASE LET ME KNOW
2 THAT YOU' RE ON THE LINE.

3 MS. FEIT: MARCY FEIT.

4 MS. KING: GREAT. THANKS, MARCY. ANYBODY
5 ELSE?

6 MR. ROTH: DUANE ROTH.

7 MS. KING: GREAT. THANKS SO MUCH, DUANE.

8 CHAIRMAN KLEIN: OKAY. DID WE FIND OUT IF
9 DR. PRICE IS ON?

10 MS. KING: HE IS ON. HE RESPONDED IN THE
11 FIRST ROLL CALL.

12 CHAIRMAN KLEIN: IS MR. LOMAX THERE?

13 DR. LOMAX: YES, I AM, BOB.

14 CHAIRMAN KLEIN: WE ARE JUST TO DISCUSS
15 THE ITEM 5 TODAY WHICH DEALS WITH STEM CELL LINES,
16 THOSE PREVIOUSLY RECOMMENDED BY OUR BOARD IN OUR
17 POLICY RECOMMENDATIONS TO THE NIH. AND GEOFF LOMAX,
18 COULD YOU LEAD THAT DISCUSSION, PLEASE?

19 DR. LOMAX: THANKS, BOB. IN RECENT WEEKS,
20 WE'VE HAD A NUMBER OF INQUIRIES REGARDING CIRM
21 GRANTEES WISHING TO USE -- THEIR QUESTION WAS THE
22 STATUS OF THE NIH LINES THAT WERE LINES UNDER FORMER
23 PRESIDENT BUSH' S POLICY, THE STATUS OF THOSE LINES
24 FOR CIRM-FUNDED RESEARCH.

25 AND WE'VE HAD -- MANY OF THESE GRANTS HAVE

BARRISTERS' REPORTING SERVICE

1 BEEN GRANTS THAT ARE THOSE LINES ARE BEING USED IN
2 CIRM-FUNDED RESEARCH. THEY' RE OLDER GRANTS. WE' VE
3 INSTRUCTED THOSE GRANTEES THAT THAT WORK CAN
4 CONTINUE. THERE HAVE BEEN SOME QUESTIONS REGARDING
5 THE STATUS OF THOSE LINES IN NEWER GRANTS. AND
6 GIVEN THE VOLUME OF INQUIRIES, I BROUGHT THIS ISSUE
7 TO THE ATTENTION OF THE CHAIRMAN' S OFFICE, ALERTING
8 THEM OF REALLY THIS IS A POLICY ISSUE. WE HAVE
9 THESE INQUIRIES, AT WHICH TIME LED TO THE DISCUSSION
10 THAT THE ORIGINAL INTENT OF THE BOARD IN PASSING THE
11 CIRM MEDICAL AND ETHICAL STANDARDS REGULATIONS IN
12 2006 WAS, IN FACT, TO ALLOW THE USE OF THESE LINES
13 MOVING FORWARD FOR ALL CIRM-FUNDED RESEARCH.

14 SO REALLY WHAT WE THOUGHT WOULD BE USEFUL
15 WAS TO MAKE A CLARIFYING STATEMENT TO THAT REGARD TO
16 THE GRANTEES AND MAKE THAT POSITION CLEAR TO THEM
17 GIVEN, AGAIN, THE VOLUME, IN FACT, THE CONFUSION
18 RIGHT NOW WITH THE FACT THAT WE HAVE A NUMBER OF
19 PREVIOUS LINES APPROVED UNDER FORMER PRESIDENT
20 BUSH' S POLICY THAT HAVE YET TO BE APPROVED FOR USE
21 BY THE NIH OR INCLUDED IN THE NIH REGISTRY.

22 SO WHAT WE' RE LOOKING FOR TODAY FROM THE
23 BOARD IS REALLY JUST A REAFFIRMATION OF THE ORIGINAL
24 POLICY THAT, IN FACT, IT WAS THE BOARD' S POSITION
25 THAT THE LINES APPROVED FOR USE UNDER FORMER

BARRISTERS' REPORTING SERVICE

1 PRESIDENT BUSH WILL CONTINUE TO BE MADE AVAIL ABLE
2 MOVING FORWARD TO CIRM GRANTEES.

3 CHAIRMAN KLEIN: AND THAT INCLUDES
4 ADDITIONAL LINES THAT ARE COMPARABLE TO CIRM'S
5 RECOMMENDATIONS TO THE NIH.

6 COULD YOU ALSO EXPLAIN OUR EXISTING POLICY
7 AS TO OTHER LINES THAT WOULD GO THROUGH THE IRB
8 PROCESS?

9 DR. LOMAX: THE MEDICAL AND ETHICAL
10 STANDARDS INCLUDE A PROVISION WHICH DESIGNATES THAT
11 THE OVERSIGHT COMMITTEE, THE DESIGNATED OVERSIGHT
12 COMMITTEE, FOR A GRANTEE HAS THE ABILITY TO UNDERGO
13 AN EVALUATION OF ANY HUMAN EMBRYONIC STEM CELL LINE.
14 AND THAT EVALUATION MUST CONSIDER WHETHER THE DONOR
15 PROVIDED INFORMED CONSENT WHEN, SAY, FOR THE
16 DONATION OF THE EMBRYO, THAT THERE WAS OVERSIGHT OF
17 THE CONSENT PROCESS BY AN IRB OR A FOREIGN
18 EQUIVALENT, AND THAT THERE WERE NO PAYMENTS MADE FOR
19 THAT DONATION.

20 IT'S A THREE-POINT TEST. AND THAT TEST,
21 IF THE OVERSIGHT COMMITTEE DETERMINES THAT THE HUMAN
22 EMBRYONIC STEM CELL LINE HAS BEEN DERIVED UNDER
23 THOSE CONDITIONS, THEN THE COMMITTEE ITSELF CAN
24 DETERMINE THAT LINE TO BE ACCEPTABLE FOR USE IN
25 CIRM-FUNDED RESEARCH.

BARRISTERS' REPORTING SERVICE

1 AND WE'VE GONE THROUGH A SERIES OF SITE
2 VISITS, WE'VE EVALUATED THE OVERSIGHT COMMITTEES;
3 AND BASED ON THESE SITE VISITS, WE'VE SEEN, IN FACT,
4 THIS PROCESS HAS -- A NUMBER OF CELL LINES HAVE
5 UNDERGONE SUCH EVALUATION, INCLUDING LINES FROM
6 EUROPE AND ASIA.

7 CHAIRMAN KLEIN: AND SPECIFICALLY YOU
8 COMMENT ON THE ABILITY TO HAVE ADOPTED THE USE OF
9 INTERNATIONAL LINES WHO HAVE EQUIVALENT STANDARDS IF
10 THEY GO THROUGH THE IRB PROCESS.

11 DR. LOMAX: THAT'S RIGHT. BUT KEEPING IN
12 MIND THAT IN SOME CASES IT WOULD BE AN IRB
13 EQUIVALENT, SOME SORT OF ETHICS OVERSIGHT COMMITTEE
14 THAT'S SERVING AS THE -- PLAYING THE IDENTICAL ROLE
15 THAT AN IRB WOULD PLAY BASICALLY IN THE UNITED
16 STATES.

17 CHAIRMAN KLEIN: AND IN TERMS OF LINES
18 DERIVED FROM SCNT OR PARTHENOGENESIS, WOULD YOU
19 COMMENT ON OUR POLICY THERE?

20 DR. LOMAX: AGAIN, WITH REGARD TO SUCH
21 LINES, THEY WOULD BE SUBJECT TO THE SAME EVALUATION
22 CRITERIA. IN THE CASE OF AN SCNT LINE, THE PAYMENT
23 PROVISION WOULD EXTEND THAT THERE WASN'T PAYMENT
24 PROVIDED FOR THE OOCYTE OR THE GAMETE IN EITHER
25 CASE. AGAIN, IT REALLY COMES DOWN TO THAT

BARRISTERS' REPORTING SERVICE

1 THREE-POINT DETERMINATION, THAT THE LINE WAS DERIVED
2 IN A MANNER WHICH WE CONSIDER TO BE ACCEPTABLY
3 DERIVED.

4 CHAIRMAN KLEIN: OKAY. DR. TROUNSON.

5 DR. TROUNSON: I THINK THERE ARE TWO
6 CRITICAL THINGS. ONE OF THEM IS THAT THE
7 GRANDFATHERING IN OF THE NIH, ORIGINAL NIH LINES,
8 THAT SET OF LINES, NOT ALL OF THEM ARE NOW APPROVED
9 BY THE NEW NIH REGULATIONS. SO I THINK THE INTENT
10 OF THE STANDARDS COMMITTEE WAS TO GRANDFATHER IN THE
11 ORIGINAL LINES. SO WE'RE ASKING FOR REAFFIRMATION
12 OF THAT ON BEHALF OF THE RESEARCHERS.

13 THE SECOND PART, GEOFF, I NOTICE THERE'S A
14 LOT OF LANGUAGE IN OUR RECOMMENDATION AND IN ALL OUR
15 DOCUMENTS TALKING ABOUT BLASTOCYSTS AND CELLS
16 DERIVED FROM THE BLASTOCYSTS, BUT OFTEN NOW THE
17 CELLS ARE SINGLE CELLS DERIVED FROM THE EMBRYO, NOT
18 THE BLASTOCYST. AND SO WHAT ARE YOU DOING TO ADJUST
19 FOR THAT BECAUSE A LOT OF LINES ARE NOT MADE FROM
20 BLASTOCYSTS ANYMORE?

21 DR. LOMAX: THE LANGUAGE IN THE
22 REGULATIONS ARE GAMETES, EMBRYOS, OR SOMATIC CELLS.
23 THAT'S THE SCOPE OF THE MATERIALS. SO WE'VE ALWAYS
24 REFERRED TO THEM AS EMBRYOS. THE BLASTOCYST
25 LANGUAGE OCCURS ACTUALLY IN THE NATIONAL ACADEMIES'

BARRISTERS' REPORTING SERVICE

1 GUIDELINES. SO I'M NOT SURE IF WE HAVE A
2 DISCREPANCY HERE. OUR LANGUAGE IS ALWAYS REFERRED
3 TO AS THE EMBRYO.

4 CHAIRMAN KLEIN: ALL RIGHT. THANK YOU
5 VERY MUCH FOR THAT RESPONSE.

6 MS. KING: I JUST WANTED TO CHECK IN. FOR
7 THE RECORD, A COUPLE OF PEOPLE HAVE JOINED THE CALL
8 AND WERE NOT CALLED IN THE ROLL. WHO JOINED THE
9 CALL?

10 DR. AZZIZ: RICARDO AZZIZ.

11 MS. KING: WHO ELSE?

12 DR. QUINT: ROBERT QUINT.

13 MS. KING: GREAT. THANK YOU SO MUCH, DR.
14 QUINT. WE NOW HAVE A QUORUM. THAT'S THE FIRST
15 THING.

16 AND THE SECOND THING, TO CHECK IN ANYONE
17 WHO'S JOINED THE CALL SINCE WE GOT STARTED, WE ARE
18 CURRENTLY DISCUSSING ITEM NO. 5, AND I WILL TURN IT
19 BACK OVER TO CHAIRMAN KLEIN.

20 CHAIRMAN KLEIN: AND FOR EVERYONE'S
21 INFORMATION, THIS IS THE ONLY ITEM WE'RE DEALING
22 WITH TODAY IS ITEM NO. 5. SO WE CAN CONTINUE
23 DISCUSSION, BUT IS THERE A MOTION TO APPROVE ITEM 5
24 SO THAT WE PROVIDE LEGAL CLARITY TO THE INSTITUTIONS
25 AND THE SCIENTISTS AS WELL AS THE FOR-PROFIT

BARRISTERS' REPORTING SERVICE

1 ENTITIES THAT ARE IN THIS FIELD THAT, IN FACT, ALL
2 OF THE PREVIOUS NIH APPROVED LINES ARE GRANDFATHERED
3 AND THAT OUR EXISTING PROCEDURES PROVIDE THAT
4 ADDITIONAL LINES CAN BE APPROVED THROUGH AN IRB
5 PROCESS THAT MEET OUR CRITERIA OR IN CASE OF
6 INTERNATIONAL LINES THROUGH EQUIVALENT CRITERIA.

7 MR. TORRES: SO MOVED.

8 CHAIRMAN KLEIN: MOVED BY ART TORRES. IS
9 THERE A SECOND?

10 DR. PRIETO: I'LL SECOND.

11 CHAIRMAN KLEIN: DR. PRIETO, THANK YOU.

12 IS THERE ADDITIONAL DISCUSSION FROM -- IS THERE
13 DISCUSSION FROM THE MEMBERS OF THE BOARD?

14 DR. AZZIZ: CAN SOMEBODY REPEAT THE MOTION
15 TO BE CLEAR?

16 CHAIRMAN KLEIN: SURE. JAMES, WOULD YOU
17 LIKE TO REPEAT THE MOTION?

18 MR. HARRISON: THE MOTION IS TO REAFFIRM
19 THAT STEM CELL LINES PREVIOUSLY APPROVED BY NIH
20 WOULD BE GRANDFATHERED IN; THAT IS, WOULD BE DEEMED
21 TO BE ACCEPTABLY DERIVED MATERIALS, AND THAT
22 ADDITIONAL LINES CAN BE APPROVED FOR USE BY
23 CIRM-FUNDED RESEARCHERS PROVIDED THAT THEY MEET THE
24 CRITERIA IN THE REGULATIONS, INCLUDING IRB APPROVAL
25 OR APPROVAL BY AN IRB-LIKE ORGANIZATION FOR

BARRISTERS' REPORTING SERVICE

1 INTERNATIONAL LINES.

2 CHAIRMAN KLEIN: AND THAT'S OUR FIRM
3 REGULATIONS?

4 MR. HARRISON: CORRECT.

5 CHAIRMAN KLEIN: AND THOSE ARE JUST
6 REAFFIRMING AND REITERATING PROVISIONS THAT ARE
7 CURRENTLY IN OUR CURRENT DOCUMENT. BUT THE
8 IMPORTANCE OF THIS IS THAT THERE'S LEGAL COUNSEL FOR
9 INSTITUTIONS THAT FELT THAT IT WAS, GIVEN
10 CONTRADICTORY POSITION BY THE NIH, WHICH HAS NOT
11 APPROVED SOME OF ITS PREVIOUSLY APPROVED LINES ON
12 WHICH A LOT OF SCIENTIFIC INVESTMENT HAS BEEN MADE
13 AND MOVED DOWNSTREAM TOWARDS CLINICAL WORK, IT'S
14 VERY IMPORTANT TO OUR LEGAL COUNSEL IN THE STATE
15 THAT WE PROVIDE CRYSTAL CLEAR REAFFIRMATION OF OUR
16 POSITION.

17 THOSE ARE THE REASONS FOR THIS PARTICULAR
18 MEETING. IS THERE ANY ADDITIONAL COMMENT FROM
19 MEMBERS OF THE BOARD? OKAY.

20 IS THERE PUBLIC AT ANY LOCATION THAT WOULD
21 LIKE TO MAKE A COMMENT? AND I START IN THE SAN
22 DIEGO AREA. IS THERE ANY COMMENT FROM THE SAN DIEGO
23 AREA?

24 MR. ROTH: NO.

25 CHAIRMAN KLEIN: IS THERE ANY COMMENT FROM

BARRISTERS' REPORTING SERVICE

1 THE LOS ANGELES AREA?

2 MS. GIBBONS: YES. IT'S LEEZA AND WE HAVE
3 JOHN SIMPSON AND BILL ADAMS HERE, AND THEY WOULD
4 WISH TO SPEAK ON THIS ISSUE.

5 CHAIRMAN KLEIN: ALL RIGHT.

6 DR. HAWGOOD: SAM HAWGOOD FROM SAN
7 FRANCISCO JUST JOINED THE CALL.

8 MR. SIMPSON: THIS IS JOHN SIMPSON. CAN
9 YOU HEAR ME OKAY?

10 CHAIRMAN KLEIN: YES, WE CAN.

11 MR. SIMPSON: I JUST WANTED TO SAY THAT
12 THIS IS AN EXCELLENT THING TO BE DOING. I MEAN THIS
13 IS COMPLETELY REAFFIRMING THE INTENT AT THE TIME.
14 IT WOULD BE TREMENDOUSLY IRONIC IF THE CELL LINES
15 THAT THE BUSH ADMINISTRATION HAD ALLOWED TO BE USED
16 COULD NOT BE USED NOW. THAT JUST MAKES NO SENSE AT
17 ALL.

18 IT'S ALSO VERY IMPORTANT, I THINK, THAT
19 YOU LEAVE OPEN THE POSSIBILITY, WHICH THE FEDS DO
20 NOT DO, FOR CELL LINES THAT ARE DERIVED BY
21 PARTHENOGENESIS. WE LEAD IN THE STATE IN THAT. WE
22 HAVE -- THAT PROCESS WAS DEVELOPED HERE. WE HAVE A
23 PRIVATE COMPANY THAT EXCELS IN THAT. IT SHOULD BE
24 PART OF ALL OF THE VARIOUS CIRM MEETINGS THAT ARE
25 DEVOTED TO THESE KINDS OF FUNCTIONS, AND I THINK

BARRISTERS' REPORTING SERVICE

1 IT'S GOOD THAT THIS IS REAFFIRMED. SO THANK YOU
2 VERY MUCH.

3 CHAIRMAN KLEIN: THANK YOU, MR. SIMPSON.

4 ADDITIONAL COMMENTS? I THINK WE HAVE AN
5 ADDITIONAL COMMENT FROM LEEZA GIBBONS' OFFICE.

6 MS. GIBBONS: NO. THAT'S IT.

7 CHAIRMAN KLEIN: OKAY. THANK YOU. SO ANY
8 ADDITIONAL COMMENTS FROM THE L. A. AREA? ADDITIONAL
9 COMMENTS FROM THE BAY AREA OUTSIDE OF SAN FRANCISCO?
10 FROM SAN FRANCISCO, DON REED.

11 MR. REED: THIS IS A GREAT THING, HAS TO
12 BE DONE, VERY SENSIBLE. I JUST HAD A QUESTION.
13 WHAT IF A CIRM PERSON TAKES A GRANT, WORKS ON THE
14 STEM CELL LINES THAT WE APPROVE, BUT IT'S NOT
15 APPROVED BY THE NIH? WOULD THEY NOT BE ELIGIBLE FOR
16 FOLLOW-ON GRANTS?

17 CHAIRMAN KLEIN: UNTIL THE NIH WERE TO
18 APPROVE THE LINE, THEY COULD NOT RECEIVE FUNDS FROM
19 THE NIH TO WORK ON THOSE LINES.

20 IS THERE ADDITIONAL COMMENT FROM THE
21 SACRAMENTO AREA?

22 DR. POMEROY: NO PUBLIC.

23 DR. PRIETO: NONE HERE.

24 CHAIRMAN KLEIN: IS THERE ANY PUBLIC FROM
25 ANY LOCATION THAT I HAVE NOT CALLED UPON? HEARING

BARRISTERS' REPORTING SERVICE

1 NONE, I WOULD LIKE TO ASK FOR ANY ADDITIONAL BOARD
2 COMMENT. GIVEN NO ADDITIONAL BOARD COMMENT, I'D
3 LIKE TO CALL THE ROLL.

4 MS. KING: FOR THE BENEFIT OF DR. SAM
5 HAWGOOD, WHO PEOPLE ON THE PHONE MAY OR MAY NOT HAVE
6 HEARD JOIN THE CALL, I WILL ASK MR. HARRISON TO
7 REPEAT THE MOTION ONE MORE TIME. THANK YOU.

8 MR. HARRISON: THIS MOTION IS TO REAFFIRM
9 THAT STEM CELL LINES PREVIOUSLY APPROVED BY NIH
10 SHOULD BE DEEMED TO BE ACCEPTABLY DERIVED UNDER
11 CIRM'S REGULATIONS AND THAT ADDITIONAL LINES MAY
12 ALSO BE USED PROVIDED THAT THEY SATISFY CIRM'S
13 REGULATIONS FOR ACCEPTABLY DERIVED MATERIALS,
14 INCLUDING APPROVAL BY AN IRB OR FOR INTERNATIONAL
15 LINES AN IRB-LIKE ENTITY.

16 CHAIRMAN KLEIN: ON EQUIVALENT STANDARDS.
17 OKAY. SO THAT IS THE MOTION. AND WE WILL PROCEED
18 WITH A ROLL.

19 MS. KING: RICARDO AZZIZ.

20 DR. AZZIZ: FOR.

21 MS. KING: ROBERT PRICE.

22 DR. PRICE: FOR.

23 MS. KING: GORDON GILL.

24 DR. GILL: FOR.

25 MS. KING: WILLIAM BRODY.

BARRISTERS' REPORTING SERVICE

1 DR. BRODY: FOR.
2 MS. KING: MARCY FEIT.
3 MS. FEIT: YES.
4 MS. KING: LEEZA GIBBONS.
5 MS. GIBBONS: YES.
6 MS. KING: SAM HAWGOOD.
7 DR. HAWGOOD: YES.
8 MS. KING: BOB KLEIN.
9 CHAIRMAN KLEIN: YES.
10 MS. KING: TED LOVE.
11 DR. LOVE: YES.
12 MS. KING: ED PENHOET.
13 DR. PENHOET: YES.
14 MS. KING: PHIL PIZZO.
15 DR. PIZZO: YES.
16 MS. KING: CLAIRE POMEROY.
17 DR. POMEROY: YES.
18 MS. KING: FRANCISCO PRIETO.
19 DR. PRIETO: AYE.
20 MS. KING: ELIZABETH FINI.
21 DR. FINI: YES.
22 MS. KING: ROBERT QUINT.
23 DR. QUINT: YES.
24 MS. KING: DUANE ROTH.
25 MR. ROTH: YES.

BARRISTERS' REPORTING SERVICE

1 MS. KING: DAVID SERRANO-SEWELL.

2 MR. SERRANO-SEWELL: YES.

3 MS. KING: JEFF SHEEHY.

4 MR. SHEEHY: YES.

5 MS. KING: OSWALD STEWARD.

6 DR. STEWARD: YES.

7 MS. KING: ART TORRES.

8 MR. TORRES: AYE.

9 MS. KING: THAT MOTION CARRIES.

10 CHAIRMAN KLEIN: OKAY. THAT IS THE ONLY
11 ITEM ON TODAY'S AGENDA. IS THERE ANY OTHER PUBLIC
12 COMMENT ON ANY OTHER TOPIC FOR TODAY?

13 MS. GIBBONS: YES. IT'S LEEZA IN LOS
14 ANGELES.

15 CHAIRMAN KLEIN: ALL RIGHT.

16 MR. SIMPSON: JOHN SIMPSON. THIS IS, I
17 THINK, MORE OF A QUESTION THAN A COMMENT. THIS, I
18 THINK, WOULD BE THE SECOND TIME THAT THE
19 CONSIDERATION OF VICE PRESIDENT FOR RESEARCH HAS
20 BEEN DROPPED FROM THE AGENDA. I'M JUST CURIOUS IF
21 YOU CAN GIVE US ANY INDICATION AS TO WHAT'S DELAYING
22 THE PROCESS?

23 CHAIRMAN KLEIN: WELL, WE CONTINUE TO
24 CALENDAR IT AND WILL FOR FLEXIBILITY IN EACH OF OUR
25 CALLS UNTIL WE HAVE GOTTEN TO A POINT THAT WE CAN

BARRISTERS' REPORTING SERVICE

1 MAKE A DECISION. IT PROVIDES US THE FLEXIBILITY TO
2 CONSIDER IT. BUT UNTIL WE GET TO THE POINT WHERE WE
3 HAVE DONE ALL OF OUR DUE DILIGENCE AND COME TO FINAL
4 TERMS, WE'RE NOT IN A POSITION TO TAKE ANY ACTION
5 IF, IN FACT, ACTION IS REQUIRED. THE PRESIDENT HAS
6 THE AUTHORITY TO HIRE THIS PERSON. AND TO THE
7 EXTENT THAT THEY NEED ANY ADDITIONAL APPROVALS FROM
8 US, WE CARRY THAT ON OUR AGENDA.

9 SO UNTIL WE'VE HIRED HIM, WE'LL CONTINUE
10 EACH TIME TO HAVE IT ON THE AGENDA BECAUSE IT GIVES
11 US FLEXIBILITY.

12 ANY OTHER QUESTIONS? HEARING NO OTHER
13 QUESTIONS, I WILL THANK EVERYONE AND WE WILL ADJOURN
14 AND WE WILL CELEBRATE THAT THIS IS A 24-MINUTE
15 MEETING.

16 (THE MEETING WAS THEN ADJOURNED AT
17 04:25 P.M.)

18
19
20
21
22
23
24
25

BARRISTERS' REPORTING SERVICE

REPORTER' S CERTI FI CATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN' S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS SPECIAL MEETING HELD ON MONDAY, MARCH 29, 2010, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152
BARRISTER' S REPORTING SERVICE
1072 BRISTOL STREET
SUITE 100
COSTA MESA, CALI FORNIA
(714) 444-4100